PeproMene Bio
PeproMene Bio is a pre-revenue, clinical-stage biotech developing first-in-class BAFF-R-targeted CAR-T, CAR-NK, and BiTE immunotherapies for relapsed/refractory B-cell malignancies and autoimmune disorders, operating virtually from Irvine, California in partnership with City of Hope.
- Company typePrivate
- Founded2017
- HeadquartersIrvine, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What PeproMene Bio does
PeproMene Bio, Inc. is a privately held, clinical-stage biotechnology company headquartered in Irvine, California, developing immune therapies that target the B-cell Activating Factor Receptor (BAFF-R) for B-cell malignancies and immune disorders. The company was founded in 2017 around technology licensed from City of Hope, where Dr. Larry Kwak's team discovered novel humanized anti-BAFF-R monoclonal antibodies that form the basis of PeproMene's programs.
The company's core product is PMB-CT01 (also designated PMB-101/PMB-102 by indication), a first-in-class autologous BAFF-R-targeted CAR T-cell therapy using anti-BAFF-R scFv antibodies with CD3ζ and 4-1BB second-generation signaling domains. PMB-CT01 is in Phase 1 trials for relapsed/refractory B-cell acute lymphoblastic leukemia (NCT04690595) and B-cell non-Hodgkin lymphoma (NCT05370430), with expansion cohorts now enrolling for mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. The pipeline also includes an allogeneic BAFF-R CAR-NK cell program intended as an off-the-shelf alternative and a BAFF-R/CD3 bispecific T-cell engager (BiTE), both built on the same BAFF-R target. PeproMene positions BAFF-R targeting as a solution to CD19 antigen-loss escape, which occurs in an estimated 20-30% of patients after CD19 CAR-T therapy.
The company operates a virtual model with 1-10 employees, relying on City of Hope as IP licensor, GMP manufacturer, and Phase 1 clinical trial site. PeproMene is pre-revenue; its capital base consists of an approximately $4M 2017 funding round and an $11M investment from the Institute for Follicular Lymphoma Innovation in December 2024 ($6M upfront plus $5M in conditional tranched funding). Commercial revenue is not expected until regulatory approval, with the company's stated future commercialization potentially including outpatient community oncology settings.
PeproMene Bio firmographics
Firmographics- Name
- PeproMene Bio
- Legal name
- PeproMene Bio, Inc.
- Website
- https://pepromenebio.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PeproMene Bio is a pre-revenue, clinical-stage biotech developing first-in-class BAFF-R-targeted CAR-T, CAR-NK, and BiTE immunotherapies for relapsed/refractory B-cell malignancies and autoimmune disorders, operating virtually from Irvine, California in partnership with City of Hope.
- Ownership category
- akta.pro rank
PeproMene Bio industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industries
- NK Cell Therapies (HLAAABAD), Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where PeproMene Bio is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
PeproMene Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Not yet monetized: PeproMene Bio is a clinical-stage biotechnology company focused on developing novel immunotherapies. The company is in Phase 1 clinical trials and has not yet generated commercial revenue. The company received an $11M investment from the Institute for Follicular Lymphoma Innovation to support clinical development.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
PeproMene Bio product offering
Product offeringCore offering
PeproMene Bio is a clinical-stage biotech developing BAFF-R (B-cell Activating Factor Receptor) targeted immunotherapies for B-cell malignancies and autoimmune disorders. Its lead candidate PMB-CT01 is a first-in-class autologous BAFF-R CAR T-cell therapy in Phase 1 trials for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). The pipeline also includes an allogeneic BAFF-R CAR-NK cell therapy and a BAFF-R/CD3 bispecific T-cell engager (BiTE).
Product overview
PeproMene Bio is developing a focused pipeline of immune therapies targeting BAFF-R (B-cell Activating Factor Receptor) for B-cell malignancies and autoimmune disorders. The core product is PMB-CT01 (BAFFR-CAR T Cells), an autologous CAR T cell therapy, which is in Phase 1 clinical trials for relapsed/refractory B-ALL and B-NHL. Complementing this are BAFFR Allo CAR NK Cells (allogeneic 'off-the-shelf' CAR NK therapy) and BAFF-R/CD3 Bispecific mAb (BAFFR BiTE), a bispecific antibody approach. All programs target the same novel BAFF-R antigen discovered at City of Hope/MD Anderson, providing a platform approach to treating B-cell cancers that have relapsed after CD19-directed therapy.
Differentiator
Problem solved
Functional benefit
Products and services
- PMB-CT01 (BAFFR-CAR T Cells) First-in-class BAFF-R-targeted autologous CAR T-cell therapy for treating relapsed/refractory B-cell malignancies including B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). Uses anti-BAFF-R scFv antibodies with second-generation signaling domains (CD3zeta and 4-1BB). Referenced as PMB-101 (r/r B-ALL, NCT04690595) and PMB-102 (r/r MCL/NHL, NCT05370430) across indications. For clinical investigators and patients with relapsed/refractory B-cell cancers including those who progressed after CD19-directed CAR-T therapy.
- BAFFR Allo CAR-NK Cells Allogeneic CAR-NK cell therapy targeting BAFF-R for treating B-cell malignancies. Unlike CAR-T cells, NK cells do not require HLA matching, enabling potential off-the-shelf therapy manufactured from allogeneic donors. For patients with B-cell cancers and potentially autoimmune disorders where an off-the-shelf cellular therapy is desired.
- BAFF-R/CD3 Bispecific mAb (BAFFR BiTE) Bispecific T-cell engager (BiTE) antibody co-targeting CD3 and BAFF-R, developed using knobs-into-holes technology. Redirects patient endogenous T cells to attack BAFF-R-expressing tumor cells. Being explored for B-cell malignancies and autoimmune disorders.
Quantifiable outcome
- 78% complete response rate (7 of 9 patients) in relapsed/refractory B-NHL including CD19 CAR-T failures
- +4 more outcomes
Companies that use PeproMene Bio
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
PeproMene Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
PeproMene Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- City of HopecoreCity of Hope is a world-renowned cancer research and treatment center that discovered the BAFF-R CAR-T technology and licensed it to PeproMene. The partnership includes collaborative manufacturing using City of Hope's GMP facilities (Cellular Therapy Production Center and Center for Biomedicine & Genetics). City of Hope conducts Phase 1 clinical trials for PMB-CT01 in B-ALL and B-NHL. Dr. Larry Kwak, who led the discovery, serves as scientific founder and chair of PeproMene's Scientific Advisory Board.
Scale indicators5 records
Recent moves6 records
Expansion highlights4 records
PeproMene Bio competitors and assessment
Company assessmentDirect peers
- Allogene Therapeutics: Allogene is a clinical-stage cell therapy company developing allogeneic CAR-T candidates for hematologic malignancies; highly comparable to PeproMene's off-the-shelf CAR-NK platform given shared modality (off-the-shelf engineered immune cells) and B-cell malignancy focus.
- Nkarta: Nkarta develops allogeneic CAR-NK cell therapies for B-cell malignancies and autoimmune disease, directly overlapping with PeproMene's BAFF-R CAR-NK program in target indication and modality.
- Fate Therapeutics: Fate develops iPSC-derived NK and T-cell immunotherapies for cancer and autoimmune disease; comparable cell therapy modality, B-cell target focus, and indication overlap with PeproMene's allogeneic CAR-NK program.
- Mustang Bio: Mustang Bio develops CAR-T cell therapies for hematologic malignancies, including B-cell cancers, making it a direct clinical-stage peer in autologous CAR-T development for r/r B-ALL and B-NHL.
- Precision BioSciences: Precision BioSciences develops in vivo and ex vivo cell therapies using ARCUS gene editing, including allogeneic CAR-T programs for B-cell malignancies; relevant comparable given shared indication space and cell therapy modality.
- Autolus Therapeutics: Autolus develops next-generation autologous CAR-T therapies for hematologic cancers, with lead programs in B-cell malignancies; closely comparable technology platform (CAR-T) and indication overlap.
- Caribou Biosciences: Caribou is a clinical-stage allogeneic CAR-T developer using CRISPR-based gene editing; comparable modality (allogeneic CAR-T) and B-cell malignancy development pipeline.
Broad incumbents
- Gilead (Kite): Gilead's Kite subsidiary markets Yescarta and Tecartus, the leading commercial CD19 CAR-T therapies for r/r B-NHL; relevant incumbent setting the standard of care that BAFF-R CAR-T must displace or complement.
- Bristol Myers Squibb: BMS markets Breyanzi (CD19 CAR-T) and Abecma (BCMA CAR-T), dominant players in cell therapy for B-cell malignancies and multiple myeloma; a key incumbent competitor and potential acquirer in the CAR-T space.
- Novartis: Novartis commercializes Kymriah, the first approved CD19 CAR-T; a broad incumbent in the CAR-T landscape and a potential strategic partner for late-stage development or commercialization of BAFF-R CAR-T.
Market position
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
PeproMene Bio social profiles
Digital presencePeproMene Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
PeproMene Bio leadership team
Management profileNumber of profiles
Profiles8 records
PeproMene Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PeproMene Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PeproMene Bio
What does PeproMene Bio do?
PeproMene Bio is a clinical-stage biotech developing BAFF-R (B-cell Activating Factor Receptor) targeted immunotherapies for B-cell malignancies and autoimmune disorders. Its lead candidate PMB-CT01 is a first-in-class autologous BAFF-R CAR T-cell therapy in Phase 1 trials for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). The pipeline also includes an allogeneic BAFF-R CAR-NK cell therapy and a BAFF-R/CD3 bispecific T-cell engager (BiTE).
Is PeproMene Bio a public or private company?
PeproMene Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was PeproMene Bio founded?
PeproMene Bio was founded in 2017. It employs 1 to 10 people.
Where is PeproMene Bio based?
PeproMene Bio is headquartered in Irvine, United States, in the North America region.
How does PeproMene Bio make money?
One revenue line is on record: not yet monetized.
Who are PeproMene Bio's main competitors?
Direct peers on record are Allogene Therapeutics, Nkarta, Fate Therapeutics, Mustang Bio, Precision BioSciences, Autolus Therapeutics and Caribou Biosciences. Broad incumbents are Gilead (Kite), Bristol Myers Squibb and Novartis.
Does PeproMene Bio have an API?
No public API is recorded for PeproMene Bio.
What industry is PeproMene Bio in?
PeproMene Bio's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAD, NK Cell Therapies. Its NAICS code is 325414 and its SIC code is 2836.